13F Pro Quality Score

44.9/100

Rank #1,745 of 2,879 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

59.2/100

Profitability

27.4/100

Balance Sheet

34.4/100

Earnings Quality

30.0/100

Free Cash Flow

25.9/100

Institutional Flow

55.9/100

Revenue Scale

71.6/100

Dilution Risk

71.0/100

BRKR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BRUKER CORP (BRKR), a Technology sector company. 13F Pro's AI-powered ranking engine scores BRKR at 44.9/100 on a 32-signal composite quality model, placing it at rank #1,745 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (25.9) and profitability (27.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), BRUKER CORP reports quarterly revenue of $823.4M, net income of $14.4M, an operating margin of 1.2%. Top institutional holders of BRKR by reported 13-F value include Orbis Allan Gray Ltd, FMR, BlackRock,, based on the most recent SEC filings. BRKR trades on the Nasdaq exchange and files with the SEC under CIK 1109354. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BRKR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BRUKER CORP directly from SEC EDGAR. BRUKER CORP's 13F Pro composite quality score has ranged between 43 and 62 since 2021, currently 44.9 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Fun facts about BRUKER CORP

Quirks, history, and lore behind BRKR — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. scientific instruments company · mid-cap · listed on Nasdaq · headquartered in Massachusetts.
  • 2
    The Numbers
    Annual revenue around $2.5 billion, with operations spanning over 90 countries — because cutting-edge science happens everywhere, and someone has to sell the tools.
  • 3
    The History
    Founded in the early 1960s, the company grew by perfecting magnetic resonance and mass spectrometry instruments long before most people knew what those words meant.
  • 4
    The Secret
    Its customers are mostly research labs, universities, and pharmaceutical companies — the kind of buyers who need to see individual atoms and molecules before breakfast.
  • 5
    The Lore
    Its NMR spectrometers are considered gold-standard tools in structural biology, and its instruments have quietly supported Nobel Prize-winning research more than once.
  • 6
    The Giveaway
    The world's leading maker of high-field NMR and mass spectrometry systems, its ticker rhymes with a certain Berkshire Hathaway abbreviation — but this one just wants to look at your proteins.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$823.4M

Net Income

Q1 2026

$14.4M

Free Cash Flow

Q1 2026

$47.0M

Operating Margin

Q1 2026

1.2%

ROIC

Q1 2026

0.3%

D/E Ratio

Q1 2026

0.68

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.1% YoY
$3.44BFY 2025
FY22 $2.53BFY23 $2.96BFY24 $3.37BFY25 $3.44B

Net Income

-107.6% YoY
$-8.6MFY 2025
FY22 $296.6MFY23 $428.5MFY24 $113.1MFY25 $-8.6M

Operating Income

-73.1% YoY
$68.2MFY 2025
FY22 $432.7MFY23 $436.9MFY24 $253.1MFY25 $68.2M

EPS (Diluted)

-119.7% YoY
$-0.15FY 2025
FY22 $1.99FY23 $2.90FY24 $0.76FY25 $-0.15

Total Assets

+7.5% YoY
$6.24BFY 2025
FY22 $3.61BFY23 $4.25BFY24 $5.81BFY25 $6.24B

Total Debt

-11.3% YoY
$1.89BFY 2025
FY22 $1.24BFY23 $1.40BFY24 $2.13BFY25 $1.89B

Op. Cash Flow

-46.6% YoY
$134.1MFY 2025
FY22 $274.4MFY23 $350.1MFY24 $251.3MFY25 $134.1M

AI Insight: BRKR Financial Trends

Debt reduction to $1,680M is a bright spot, but operating income collapsed to $10M in Q1 2026 — near the weakest level in the dataset.

Total debt declined steadily from $2,491M in Q2 2025 to $1,680M in Q1 2026, the lowest level shown.

Operating income fell sharply from $76M in Q4 2025 to $10M in Q1 2026, matching the weakest quarterly print in the table.

Revenue has been range-bound: Q1 quarters print ~$800–823M while Q4 quarters reach ~$977–980M, suggesting seasonal but not secular growth.

Operating cash flow turned deeply negative at -$128M in Q2 2025 and -$33M in Q3 2025, before recovering to $230M in Q4 2025.

Net income swung to -$60M in Q3 2025 — first loss in the dataset — signaling potential one-time or structural cost pressure worth monitoring.

Operating cash flow of $71M in Q1 2026 versus $10M operating income suggests working-capital timing; sustainability of cash conversion needs watching.

Equity rebounded to $2,456M in Q4 2025 from $1,781M in Q4 2024; confirming the driver — earnings vs. issuance — is key to assessing balance-sheet quality.

AI Insight: BRKR Ratio Trends

Bruker's profitability has collapsed to near-zero on a TTM basis, with operating margin of just 1.4% and ROIC of 2.8% after a severe Q3 2025 loss.

Operating margin swung from -6.0% in Q3 2025 to 7.8% in Q4 2025, but reverted to 1.2% in Q1 2026, signaling no durable recovery.

TTM net profit margin is -0.3% and ROIC is 2.8%, both near multi-period lows versus Q3 2024's 4.7% NPM and 6.6% ROIC.

Debt-to-equity improved from 1.29 in Q3 2024 to 0.77 in Q4 2025, the only notable balance-sheet positive in recent quarters.

Q3 2025 saw ROE of -9.8% and ROIC of -4.6% — a sharp single-quarter deterioration; monitor whether Q1 2026's weakness signals a repeat.

ROIC has dropped from 7.4% in Q4 2024 to 2.4% in Q1 2026 — watch for sustained return above cost of capital.

D/E decline to 0.77 in Q4 2025 is a positive inflection; confirm trend holds as profitability pressures persist.

Get alerted when BRKR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BRUKER CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of BRKR

Put BRKR on your watchlist

Track score changes the day BRUKER CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is BRKR a good stock to buy?

13F Pro's AI-powered analysis of BRUKER CORP (BRKR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BRKR are available on the BRKR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BRKR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BRKR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BRUKER CORP's investment landscape.